科室团队详细页面

[中文期刊] Characteristics of lipid metabolism-related gene expression-based molecular subtype in papillary thyroid cancer 剑桥 CA CSCD

作者： Midie Xu，Tuanqi Sun，Shishuai Wen，Tingting Zhang，Xin Wang，Yiming Cao，Yu Wang，Xing Sun，Qinghai Ji，Rongliang Shi，Ning Qu （Department of Pathology，Fudan University Shanghai Cancer Center，Shanghai 200032，China；Department of oncology，Shanghai Medical College，Fudan University，Shanghai 200032，China；Institute of Pathology，Fudan University，Shanghai 200032，China；Department of Head and Neck Surgery，Fudan University Shanghai Cancer Center，Shanghai 200032，China；Department of General Surgery，Shanghai First People\'s Hospital，School of Medicine，Shanghai Jiao Tong University，Shanghai 201620，China）

出处：生物化学与生物物理学报(英文版) 2020 第52卷第10期 P1166-1170

关键词： METABOLISM；CANCER；PAPILLARY

摘要： Metabolic reprogramming has been recognized as one of the 10 new hallmarks of cancer cells \'(1)\'.Increased glycolysis (Warburg effect) under normoxi ...

[中文期刊] COVID-19-associated gastrointestinal and liver injury: clinical features and potential mechanisms CSCD

作者： Zhong Peijie，Xu Jing，Yang Dong，Shen Yue，Wang Lu，Feng Yun，Du Chunling，Song Yuanlin，Wu Chaomin，Hu Xianglin，Sun Yangbai （Department of Musculoskeletal Surgery，Fudan University Shanghai Cancer Center；Department of Oncology，Shanghai Medical College，Fudan University；Department of Gastroenterology and Hepatology，Huaihe Hospital of Henan University；Clinical Medical Colleg；Department of Endocrinology and Metabolism，Zhongshan Hospital，Fudan University；Department of Pulmonary and Critical Care Medicine，Zhongshan Hospital，Fudan University；Department of Gastroenterology and Hepatology，Zhongshan Hospital，Fudan University；Department of Gastroenterology and Hepatology，Shanghai General Hospital，Shanghai Jiao Tong University School of Medicine；Department of Pulmonary and Critical Care Medicine，QingPu Branch of Zhongshan Hospital Affiliated to Fudan University；Department of Sur）

出处： Signal Transduction and Targeted Therapy 2020 第5卷第4期 P2211-2218

摘要： Coronavirus disease-2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The infection is spreading globally and ...

[中文期刊] Excipient-free porphyrin/SN-38 based nanotheranostics for drug delivery and cell imaging CSCD

作者： Yuan Ye，Bo Ruonan，Jing Di，Ma Zhao，Wang Zhongling，Lin Tzuyin，Dong Lijie，Xue Xiangdong，Li Yuanpei （Center for Smart Materials and Devices，Wuhan University of Technology，State Key Laboratory of Advanced Technology for Materials Synthesis and Processing；Department of Biochemistry and Molecular Medicine，UC Davis Comprehensive Cancer Center，University of California Davis；School of Veterinary Medicine，Yangzhou University；Department of Oncology，Xiangya Hospital，Central South University；Department of Radiology，Shanghai General Hospital，Shanghai Jiao Tong University School of Medicine；Division of Hematology/Oncology，Department of Internal Medicine，University of California Davis；College of Life Sciences，Northwest University）

出处： Nano Research 2020 第13卷第2期 P503-510

关键词： porphyrin；7-ethyl-10-hydroxy-camptothecin；(SN-38)；drug；delivery；self-indication；nanotheranostics；photodynamic；therapy

摘要： Nanotheranostics with comprehensive diagnostic and therapeutic capabilities show exciting cancer treatment potentials.Here, we develop an excipient-fr ...

[外文期刊] Adjuvant Capecitabine With Docetaxel and Cyclophosphamide Plus Epirubicin for Triple-Negative Breast Cancer (CBCSG010): An Open-Label, Randomized, Multicenter, Phase III Trial. SCI

作者： Junjie Li;Keda Yu;Da Pang;Changqin Wang;Jun Jiang;Suisheng Yang;Yunjiang Liu;Peifen Fu;Yuan Shen;Guojun Zhang;Yali Cao;Qi He;Shude Cui;Xijing Wang;Guosheng Ren;Xinzheng Li;Shiyou Yu;Pengxi Liu;Xiang Qu;Jinhai Tang;Ouchen Wang;Zhimin Fan;Guoqin Jiang;Jin Zhang;Jiandong Wang;Hongwei Zhang;Shui Wang;Jianguo Zhang;Feng Jin;Nanyan Rao;Binlin Ma;Pingqing He;Binghe Xu;Zhigang Zhuang;Jianfeng Wang;Qiang Sun;Xiaofeng Guo;Miao Mo;Zhimin Shao （Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, People\'s Republic of China. Department of Oncology, Shanghai Medical College, Fudan University, Key Laboratory of Breast Cancer in Shanghai, Shanghai, People\'s Republic of China. Department of Breast Surgery, The Third Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, People\'s Republic of China. Department of Breast Surgery, Jilin Cancer Hospital and Institute, Changchun, Jilin, People\'s Republic of China. Department of Breast Surgery, Southwest Hospital, Chongqing, Chongqing, People\'s Republic of China. Department of Breast Surgery, Gansu Cancer Hospital, Lanzhou, Gansu, People\'s Republic of China. Department of Breast Surgery, The Fourth Clinical Medical College of Hebei Medical University, Shijiazhuang, Hebei, People\'s Republic of China. Department of Breast Surgery, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, People\'s Republic of China. Department of Breast Surgery, Changhai Hospital of Shanghai, Shanghai, People\'s Republic of China. Department of Breast Surgery, Cancer Hospital of Shantou Medical College, Shantou, Guangdong, People\'s Republic of China. Department of Breast Surgery, The Third Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, People\'s Republic of China. Department of Breast Surgery, The International Peace Maternity and Child Health Hospital of China Welfare Institute, Shanghai, People\'s Republic of China. Department of Breast Surgery, Henan Cancer Hospital Affiliated to Zhengzhou University, Zhengzhou, Henan, People\'s Republic of China. Department of Breast Surgery, Medical College, The Second Affiliated Hospital of Xi\'An Jiaotong University, Xi\'an, Shanxi, People\'s Republic of China. Department of Breast Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, People\'s Republic of China. Department of Breast Surgery, Shanxi Cancer Hospital, Taiyuan, Shanxi, People\'s Republic of China. Department of Oncology, Eastern Hospital of Suzhou Municipal Hospital, Suzhou, Jiangsu, People\'s Republic of China. Department of Breast Surgery, Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou, Guangdong, People\'s Republic of China. Department of General Surgery, Beijing Friendship Hospital, Capital Medical University, Beijing, People\'s Republic of China. Department of Breast Surgery, Jiangsu Cancer Hospital, Suzhou, Jiangsu, People\'s Republic of China. Department of Oncology, The First Hospital of Wenzhou Medical College, Wenzhou, Zhejiang, People\'s Republic of China. Department of Breast Surgery, The First Hospital of Jilin University, Changchun, Jilin, People\'s Republic of China. Department of General Surgery, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, People\'s Republic of China. Department of Breast Surgery, Tianjin Medical University Cancer Institute and Hospital, Tianjin, People\'s Republic of China. Department of General Surgery, The General Hospital of the People\'s Liberation Army, Beijing, People\'s Republic of China. Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, People\'s Republic of China. Department of Breast Surgery, Jiangsu Province Hospital, Suzhou, Jiangsu, People\'s Republic of China. Department of Breast Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, People\'s Republic of China. Department of Breast Surgery, The First Hospital of China Medical University, Shenyang, Liaoning, People\'s Republic of China. Department of Breast Surgery, The Second Affiliated Hospital of Zhongshan University, Guangzhou, Guangdong, People\'s Republic of China. Department of Breast Surgery, Xinjiang Cancer Hospital, Wulumuqi, Xinjiang, People\'s Republic of China. Department of Breast Surgery, Shanghai Sixth People\'s Hospital, Shanghai, People\'s Republic of China. Department of Medical Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, People\'s Republic of China. Department of Breast Surgery, Shanghai First Maternity and Infant Hospital Corporation, Shanghai, People\'s Republic of China. Department of General Surgery, Shanghai General Hospital, Shanghai, People\'s Republic of China. Department of Breast Surgery, Peking Union Medical College Hospital, Beijing, People\'s Republic of China. Continuing Education and Technology Services Department, Chinese Anti-Cancer Association, Tianjin, People\'s Republic of China. Department of Cancer Prevention, Fudan University Shanghai Cancer Center, and Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People\'s Republic of China.）

出处： Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2020 PJCO1902474

摘要： PURPOSE: Standard adjuvant chemotherapy for triple-negative breast cancer (TNBC) includes a taxane and an anthracycline. Concomitant capecitabine may ...

[中文专利] 一种两性离子修饰树状大分子包裹金纳米颗粒/HIF-1αsiRNA复合物的制备

发明人：史向阳，杨超，高悦，曹雪雁，肖云超，曹流，宋聪，李锦，刘勇

申请号： 202010430439.3

申请日期： 2020.05.20

摘要：本发明涉及一种两性离子修饰树状大分子包裹金纳米颗粒/HIF‑1αsiRNA复合物的制备方法。该制备方法包括：G5.NH 2 ‑PS 20 溶液制备；{(Au 0 ) 25 ‑G5.NH 2 ‑PS 20 }制备；{(Au 0 ) 25 ‑G5.NH 2 ‑PS 20 }/si‑HIF‑1α制备。该方 ...

[中文专利] 一种乳腺癌类器官的培养方法以及和肿瘤相关成纤维细胞的共培养方法

发明人：王红霞，周天浩，鞠高达，杜少倩

申请号： 202010796528.X

申请日期： 2020.08.10

摘要：本发明涉及一种乳腺癌类器官的培养方法以及和肿瘤相关成纤维细胞的共培养方法。本发明建立了更加高效便捷的乳腺癌患者肿瘤组织类器官(PDO)培养、传代与维持等关键技术环节的改进体系，包括多方面简化PDO细胞系建立、传代的操作步骤和方法，优化培养基、消化液和洗涤液成分等，最终成功建立乳腺癌PDO培养体系，相 ...

[外文期刊] The combination of PKM2 overexpression and M2 macrophages infiltration confers a poor prognosis for PDAC patients. SCI

作者： Hai Hu;Wenzhi Tu;Yungu Chen;Ming Zhu;Huan Jin;Ting Huang;Zhengzhi Zou;Qing Xia （Department of Oncology, State Key Laboratory for Oncogenes and Related Genes, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai Cancer Institute, Shanghai, 200127, China. The Comprehensive Cancer Center, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 201620, China. Department of Obstetrics and Gynecology, Shanghai General Hospital, Shanghai JiaoTong University School of Medicine, Shanghai 201620, China. MOE Key Laboratory of Laser Life Science &Guangdong Provincial Key Laboratory of Laser Life Science, College of Biophotonics, South China Normal University, Guangzhou, Guangdong 510631, China.）

出处： Journal of Cancer 2020

关键词： PDAC;PKM2;macrophage;prognosis

摘要： Macrophages play a critical role in the initiation and progression in various human solid tumors; however, their role and transformation in pancreatic ...

[外文期刊] MiR-612 regulates invadopodia of hepatocellular carcinoma by HADHA-mediated lipid reprogramming.

作者： Liu, Yang;Lu, Li-Li;Wen, Duo;Liu, Dong-Li;Dong, Li-Li;Gao, Dong-Mei;Bian, Xin-Yu;Zhou, Jian;Fan, Jia;Wu, Wei-Zhong （1 Liver Cancer Institute, Zhongshan Hospital, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Fudan University, 180 Fenglin Road, 200032, Shanghai, China 2 Department of Oral Maxillofacial-Head and Neck Oncology, Shanghai Ninth People\'s Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China 3 Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, 200032, Shanghai, China 4 Department of Radiation Oncology, Shanghai General Hospital, Shanghai Jiaotong University, 200080, Shanghai, China 5 Department of Liver Surgery and Transplantation, Zhongshan Hospital, Fudan University, 200032, Shanghai, China）

出处： Journal of Hematology & Oncology 2020 Vol.13 No.1 P1-19

关键词： β-Oxidation;Hepatocellular carcinoma;Invadopodia;Metastasis;miR-612

摘要： Background: MicroRNA-612 (miR-612) has been proven to suppress EMT, stemness, and tumor metastasis of hepatocellular carcinoma (HCC) via PI3K/AKT2 and ...

[中文期刊] PD-1/PD-L1抑制剂免疫相关不良反应的研究进展剑桥 CA 文摘源

作者：徐一清，刘勇（上海交通大学医学院；上海市第一人民医院肿瘤中心放疗科）

出处：实用肿瘤杂志 2020

关键词：肿瘤；PD-1/PD-L1抑制剂；免疫相关不良反应；免疫

摘要：近年来免疫治疗已成为继手术、放疗、化疗和靶向治疗外的第5种肿瘤治疗手段,具有缓解率高和疾病谱广等优点,受到广泛临床关注。程序性死亡受体1(programmed cell death-1,PD-1)/程序性死亡受体-配体1(programmed cell death-ligand 1,PD-L1)抑制 ...

[中文期刊] 去泛素化酶在肝癌发生发展中的研究进展* 核 CA 源 CSCD

作者：贾雪冰，李琦（上海交通大学附属第一人民医院肿瘤中心）

出处：中国肿瘤临床 2020

关键词：肝癌；去泛素化酶；去泛素化酶抑制剂

摘要：泛素-蛋白酶体途径(ubiquitin-proteasome pathway,UPP)是细胞内蛋白降解的重要调节系统。近年来的研究发现,去泛素化酶在肝癌中发挥重要作用。去泛素化酶可以逆转蛋白质泛素化降解过程,进而影响肿瘤的发生发展过程,包括凋亡和自噬、肿瘤的信号通路、细胞周期的调节和DNA损伤等。小 ...